Cradesha Perry, PharmD, MBA

home / authors / cradesha-perry-pharmd-mba

Articles

Chronic lymphocytic leukemia -- Image credit: LASZLO | stock.adobe.com

Chronic Lymphocytic Leukemia: A Review of Noncovalent BTK Inhibitors, Novel Agents, and Toxicity Management of BTK Inhibitors

Richa Shah, PharmD, BCOP;Jessie Modlin, PharmD, BCOP;Rezarta Lako, PharmD, BCPS;Yuxi Lei, PharmD;Adina Kagan, PharmD Candidate;Cradesha Perry, PharmD, MBA;Luisa Giannangelo, MBA, RPh;Rebecca Pokorny, PharmD, BCPS, BCOP;Kevin Pang, PharmD

August 19th 2024

This article discusses clinical data for noncovalent Bruton tyrosine kinase inhibitors (BTKis), novel strategies in CLL, and the practical management of BTKi toxicities.

CLL in blood -- Image credit: Dr_Microbe | stock.adobe.com

Covalent BTK Inhibitors: A Review of the Evidence in Chronic Lymphocytic Leukemia

Richa Shah, PharmD, BCOP;Rebecca Pokorny, PharmD, BCPS, BCOP;Luisa Giannangelo, MBA, RPh;Cradesha Perry, PharmD, MBA;Adina Kagan, PharmD Candidate;Yuxi Lei, PharmD;Rezarta Lako, PharmD, BCPS;Jessie Modlin, PharmD, BCOP;Kevin Pang, PharmD

June 14th 2024

This article provides an overview of data supporting the utility of covalent Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia and details important considerations when choosing among agents.